• Explore /
  • Poster
  • / First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

Abstract Video & Slides Poster

Authors

Luis Paz-Ares

Luis G. Paz-Ares

Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain

Luis G. Paz-Ares , Tudor-Eliade Ciuleanu , Manuel Cobo-Dols , Jaafar Bennouna , Ying Cheng , Hideaki Mizutani , Alejo Lingua , Felipe Reyes , Niels Reinmuth , Juliana Janoski De Menezes , Jacek Jassem , Svetlana Protsenko , Kynan Feeney , Emmanuel De La Mora Jimenez , Shun Lu , Tom John , David Paul Carbone , Xiaoqing Zhang , Nan Hu , Martin Reck

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03215706

Citation

J Clin Oncol 40, 2022 (suppl 17; abstr LBA9026)

DOI

10.1200/JCO.2022.40.17_suppl.LBA9026

Abstract #

LBA9026

Poster Bd #

14

Abstract Disclosures

Similar Posters

First Author: Julie R. Brahmer

First Author: David Paul Carbone

First Author: Patrick M. Forde

First Author: Luis G. Paz-Ares